Our model is to follow in the footsteps of drugs like Keytruda, Revlimib, and Opdivo, and take our lead molecule (which has broad therapeutic potential) and begin commercializing with the Orphan disease Eosinophilic Esophagitis, for which there is currently no FDA drug approved. The average annual cost for an orphan drug is $100,000. With 150K patients in the TAM, there is a $15B annual revenue. We will then expand into the 30% of patients of severe asthma that are discontinuing biologics, for which there is a TAM of 450K patients and an average drug price for this population being $30K annually, leading to $13B annual revenue.

Our competitive advantage is that we have potent therapeutic effects that can help patients with severe disease, but do not have any known toxicities. We also target multiple inflammatory cell types rather that one, positioning us to outcompete biologics.

If you look at Merck, BMS and J&J's top selling drugs in 2020 (Keytruda, Revlimib and Opdivo) their strategies have been to stack approvals for one segment of a patient population at a time. This allows for more targeted, successful clinical trials, year after year. We aim to take the same approach for allergic and autoimmune disease, knowing that there is great heterogeneity in these patients and that a piecemeal approach has led to the most successful revenue streams.